Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 82.35

-4.5%

Jan 8 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1857)	1/16/2008 11:57:25 AM
From: Jibacoa	Read Replies (1) of 3722

EPIX is down 17.4% after it said there were some errors made in the transcription of data and calculation of the ADAS-cog score,& an independent re-analysis of the data has been conducted, but is now down only 11.48% <g> EPIX has now fully closed its Dec18 UG & should be able to make a base above the $3 level.<g> bigcharts.marketwatch.com EPIX said that the corrected results still show that patients receiving 150 mg of PRX-03140 orally once daily as monotherapy achieved a mean 3.6 point improvement on the ADAS-cog versus a 0.9 point worsening in patients on placebo, which continues to be statistically significant (p= 0.021). Data for the patients on a 50 mg dose showed a 1.0 point improvement on the ADAS-cog. The monotherapy dose response (150 mg versus 50 mg versus placebo) continues to be statistically significant with p=0.026. The reported safety results from the trial were unchanged. In spite of the general market & EPIX large negative CF, the stock's R/R doesn't look bad at present levels. The last private placement in Nov was at $3.10/shr. I will keep a mental target for EPIX around $5 in 2008, which is about the analyst's consensus.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next